FDA-approved
Orforglipron
A once-daily GLP-1 pill with no food or water rules.
KEY EVIDENCE
ATTAIN-1
VIDEO LESSON
How it's taken
• Once-daily pill, with or without food
• The dose is increased in steps to reduce side effects
Side effects at a glance
• Nausea, vomiting, diarrhea and constipation, mostly during dose increases
Rare but serious
Class-wide GLP-1 cautions apply, including pancreatitis and gallbladder disease.
Good to know
A small-molecule GLP-1 pill can suit people who prefer to avoid injections and avoids the fasting rules of oral semaglutide.
AT A GLANCE
Type
Medication
Brand names
Foundayo
Status
FDA-approved
Reviewed by
Farhan Tahir, MD
Is this treatment right for you?
Prescription medicines and procedures need individual medical advice. Dr. Tahir’s team offers consults through Youthful Medicine.
How it works
A small-molecule (non-peptide) GLP-1 receptor agonist (Foundayo). Because it is not a peptide, it is absorbed without the fasting and water timing that oral semaglutide needs.
What the evidence shows
In ATTAIN-1, adults with obesity on the 36 mg dose lost a mean 11.2% of body weight over 72 weeks versus 2.1% on placebo, with improvements in waist size, blood pressure and cholesterol. The FDA approved it on April 1, 2026 after a 50-day priority review.
Side effects & cautions
Side effects are mainly gastrointestinal; 5–10% of trial participants stopped because of them, compared with about 3% on placebo. Class-wide GLP-1 cautions apply.
TYPICAL RESULT IN TRIALS
≈11% mean weight loss at 72 weeks (36 mg)
PHYSICIAN FIRST
Is this right for you?
Prescription treatments need a review of your history, labs and other medicines. Never start or stop one on your own.